Recent progress in TGF-β inhibitors for cancer therapy
Transforming growth factor-β (TGF-β) is a multifunctional cytokine that is involved in proliferation, metastasis, and many other important processes in malignancy. Inhibitors targeting TGF-β have been considered by pharmaceutical companies for cancer therapy, and some of them are in clinical trial n...
Main Authors: | Cheng-Yi Huang, Chih-Ling Chung, Tsung-Hui Hu, Jih-Jung Chen, Pei-Feng Liu, Chun-Lin Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-02-01
|
Series: | Biomedicine & Pharmacotherapy |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332220312385 |
Similar Items
-
Roles of Myosin-Mediated Membrane Trafficking in TGF-β Signaling
by: Chih-Ling Chung, et al.
Published: (2019-08-01) -
Pentabromopseudilin: a myosin V inhibitor suppresses TGF-β activity by recruiting the type II TGF-β receptor to lysosomal degradation
by: Wang Shih-Wei, et al.
Published: (2018-01-01) -
Novel therapies emerging in oncology to target the TGF-β pathway
by: Byung-Gyu Kim, et al.
Published: (2021-04-01) -
TGFβ1-induced SMAD2/3 and SMAD1/5 phosphorylation are both ALK5-kinase-dependent in primary chondrocytes and mediated by TAK1 kinase activity
by: Arjan van Caam, et al.
Published: (2017-05-01) -
Non-specificity of Pitstop 2 in clathrin-mediated endocytosis
by: Anna K. Willox, et al.
Published: (2014-04-01)